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recovered and were discharged within
1 to 6 days.
The 3.4% incidence of HBoV
observed in our study is similar to that
(3.1%) reported by Allander et al. (2).
HBoV was the only infectious agent
identified in 6 children, which sug-
gests that it was the causative agent of
the disease. However, more studies
conducted in children with and with-
out respiratory disease as well as in
adults and elderly persons are needed
to better assess the pathogenic role of
HBoV. 
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Extended-spectrum
β-Lactamase–
producing
Enterobacteriaceae,
Central African
Republic
To the Editor: Since the early
1980s, extended-spectrum β-lacta-
mases (ESBLs) have been the largest
source of resistance to broad-spec-
trum oxyimino-cephalosporins among
Enterobacteriaceae (1). Molecular
analysis techniques suggest that many
ESBLs are derived from mutations in
TEM-1, TEM-2, and SHV-1 β-lacta-
mases and that these ESBLs can
hydrolyze the extended-spectrum
cephalosporins (particularly cef-
tazidime) and aztreonam (1).
Members of a new group of ESBLs
have been recently identified (1).
Among them, CTX-M–type ESBLs
are rapidly expanding and are derived
from chromosomal class A β-lacta-
mases of Kluyvera spp. (1,2). The
CTX-M enzymes are not related to
TEM or SHV enzymes, as they share
only 40% identity with these ESBLs
(2).These ESBLS are usually charac-
terized by a higher level of resistance
to cefotaxime than ceftazidime,
except for CTX-M-19 (2). Most
organisms that harbor ESBLs are also
resistant to other classes of antimicro-
bial drugs, such as aminoglycosides,
fluoroquinolones, chloramphenicol,
and tetracyclines (1,2).
Reports concerning the existence
of ESBL-producing Enterobac-
teriaceae in sub-Saharan Africa are
scarce. We therefore conducted a
study in the Central African Republic
to determine the frequency of ESBLs
in Enterobacteriaceae isolated at the
Institut Pasteur de Bangui and to char-
acterize their blaTEM,  blaSHV, and
blaCTX-M genes.
From January 2003 to March
2005, all Enterobacteriaceae isolated
from human specimens at the Institut
Pasteur de Bangui were screened for
ESBLs. Antimicrobial drug suscepti-
bility was determined by using the
disk diffusion method (Bio-Rad,
Marnes la Coquette, France) on
Mueller-Hinton agar (MHA) and
interpreted according to the recom-
mendations of the Comité de
l’Antibiogramme de la SociétéLETTERS
Française de Microbiologie (CA-
SFM) (www.sfm.asso.fr). ESBL-pro-
ducing  Enterobacteriaceae were
selected by the following criteria: sus-
ceptibility to cefoxitin; decreased sus-
ceptibility to cefotaxime (30 µg), cef-
tazidime (30 µg), or cefepime (30 µg)
(zone diameter <21 mm); and
enhanced susceptibility in the pres-
ence of clavulanic acid by the double
disk synergy test (3). For suspected
ESBLs, the MICs of broad-spectrum
cephalosporins were determined by
using the agar dilution method.
We screened 450 Entero-
bacteriaceae for ESBLs during the
study. We isolated and identified 17
(4%) ESBL-producing strains (Table).
These strains were associated with
urinary tract infection, pneumonia in
an AIDS patient, wound infection,
vaginal or intestinal colonization, and
ear infection. We found that 11 iso-
lates were more resistant to cefo-
taxime (MIC >256  µg/mL) than to
ceftazidime (MIC <128  µg/mL),
which suggests CTX-M–type
enzymes.  Enterobacteriaceae strains
that harbor ESBLs were frequently
associated with resistance to amino-
glycosides and ciprofloxacin (Table).
The conjugal transfer of the resist-
ance determinants was carried out in
trypticase soy (TS) broth with
rifampin-resistant  Escherichia coli
J53-2 as the recipient. Mating broths
were incubated at 37°C for 18 h.
Transconjugants were selected on
MHA plates containing rifampin (250
µg/mL) and cefotaxime (2.5 µg/mL).
If conjugal transfer failed, plasmid
DNA was extracted from donors with
the Qiagen Plasmid Mini Kit (Qiagen,
Courtaboeuf, France); 20 µLof E. coli
DH10B cells were transformed with
plasmid DNA by electroporation
according to the manufacturer’s
instructions (Bio-Rad). Transformants
were incubated for 1.5 h at 37°C in TS
broth and then plated on MHA plates
supplemented with 2.5 µg/mL cefo-
taxime.
Plasmid-encoded  β-lactamase
genes were detected on clinical iso-
lates and their tranconjugants or trans-
formants by polymerase chain reac-
tion with oligonucleotide primer sets
specific for the blaTEM,  blaSHV, and
blaCTX-M genes (4). PCR assays were
performed on total DNA extracted by
using the commercial Qiagen DNA
Mini Kit. The 3 β-lactamase genes
were detected in different clinical iso-
lates (Table). PCR results showed that
the strains were harboring >2 different
types of β-lactamases.
Plasmid-encoded  β-lactamase
genes were characterized by direct
DNA sequencing with PCR primers.
The nucleotide sequences were ana-
lyzed by the BLASTN (nucleotide
basic local alignment search tool) pro-
gram. For ESBLs, the gene types
(SHV-2a, SHV-12, CTX-M-15, and
CTX-M-3) were identified from dif-
ferent  Enterobacteriaceae (Table).
Only 1 strain (Enterobacter aero-
genes) harbored 2 different ESBLs
(CTX-M-3 and SHV-12). We identi-
fied TEM-1 and CTX-M15 enzymes,
which are the most prevalent β-lacta-
mases detected in our strains.
ESBL-producing  Enterobac-
teriaceae have been previously
described in South Africa (5), Kenya
(6), Senegal (7), Cameroon (8),
Tanzania (9), and Nigeria (10). As
described in these countries, we found
that CTX-M-15, SHV-2a, and SHV-
12 were the most prevalent enzymes.
CTX-M-15, the most recently
described ESBL type, is particularly
common in Bangui and seems to be
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closely related to E. coli, as was pre-
viously observed in Tanzania (9). This
finding is also the first report of CTX-
M-3 in sub-Saharan Africa.
Multidrug resistance profiles
involving non–β-lactam antimicrobial
drugs coselected these ESBL-produc-
ing isolates. We suggest that the mis-
use of antimicrobial drugs in the
Central African Republic and the
migratory flux of regional populations
could result in emergence and selec-
tion of these ESBL phenotypes in the
community. We could not establish a
relationship between the different
strains isolated in hospitalized and
ambulatory patients. Because of the
implications for treating such infec-
tions, particularly in developing coun-
tries, the spread of ESBL-producing
Enterobacteriaceae merits close sur-
veillance in the Central African
Republic.
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Novel Recombinant
Sapovirus, Japan 
To the Editor: Sapovirus is the
distinct genus within the family
Caliciviridae; these viruses cause spo-
radic cases and outbreaks of gastroen-
teritis in humans worldwide (1). The
sapovirus genome contains 2 open
reading frames (ORFs). ORF1
encodes nonstructural and capsid pro-
teins while ORF2 encodes a small pro-
tein (2). Sapovirus has a typical “Star
of David” configuration by electron
microscopic examination. The proto-
type sapovirus is the Sapporo virus
(Hu/SaV/Sapporo virus/1977/ JP),
which was originally discovered from
an outbreak in a home for infants in
Sapporo, Japan, in 1977 (3). Sapovirus
is divided into 5 genogroups, among
which only genogroups I, II, IV, and V
are known to infect humans (4).
A fecal specimen was collected
from a 1-year-old boy with acute gas-
troenteritis in Osaka, Japan, in March
2005. The viral genome was extracted
by using a QIAamp kit (Quigen,
Hilden, Germany). By using multi-
plex reverse transcription–polymerase
chain reaction (RT-PCR), 2 groups of
diarrheal viruses were identified. The
first group included astrovirus,
norovirus, and sapovirus; the second
group included rotavirus and aden-
ovirus (5). Sapovirus polymerase
region was also amplified to identify
recombinant sapovirus by using
primers P290 and P289 (6). To elimi-
nate the possibility of co-infection of
2 different sapovirus genotypes, to
localize the potential recombination
site, and to understand a possible
recombination mechanism of recom-
binant sapovirus, flanking polymerase
and capsid regions, with their junction
of HU/5862/Osaka/JP, were amplified
with primers P290 and SLV5749 to
produce a 1,162-bp product (5,6).
Products were directly sequenced, and
capsid- and polymerase-based phylo-
genetic trees showed recombinant
sapovirus.
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